Trial Title:
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
NCT ID:
NCT06328387
Condition:
Advanced Breast Cancer
Metastatic Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Hydroxychloroquine
Trastuzumab
Sacituzumab govitecan
Trastuzumab deruxtecan
Conditions: Keywords:
Antibody-drug Conjugate
Hydroxychloroquine
Advanced Breast Cancer
Metastatic Breast Cancer
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Parallel Assignment
Intervention model description:
The research model consists of four arms:
1. arm A: SG.
2. arm B: HCQ+SG.
3. arm C: T-DXd .
4. arm D: HCQ+T-DXd.
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Hydroxychloroquine
Description:
The dosage of hydroxychloroquine is determined based on the dose escalation study, and
the appropriate administration method will be determined based on this result.
Arm group label:
Hydroxychloroquine Combined With Sacituzumab Govitecan
Arm group label:
Hydroxychloroquine Combined With Trastuzumab Deruxtecan
Other name:
Plaquenil
Intervention type:
Drug
Intervention name:
Sacituzumab Govitecan
Description:
Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a
chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it
attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors,
and delivers govitecan to kill them.
Arm group label:
Hydroxychloroquine Combined With Sacituzumab Govitecan
Arm group label:
Sacituzumab Govitecan
Other name:
IMMU-132
Other name:
Trodelvy™
Other name:
GS-0132
Intervention type:
Drug
Intervention name:
Trastuzumab Deruxtecan
Description:
Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of
humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same
amino acid sequence as trastuzumab, covalently linked to the membrane-permeable
topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable
tetrapeptide-based linker, selectively cleaved within tumor cells.
Arm group label:
Hydroxychloroquine Combined With Trastuzumab Deruxtecan
Arm group label:
Trastuzumab Deruxtecan
Other name:
DS-8201
Other name:
Enhertu
Summary:
Advanced breast cancer is a special subtype of human breast cancer. Conventional
guidelines recommend chemotherapy combined with other adjuvant therapies for this subtype
of patients. However, the choice of treatment for these patients after treatment progress
is a research hotspot in this field. Trastuzumab Deruxtecan (T-DXd) and Sacituzumab
Govitecan (SG) are new ADC drugs targeting HER2 or TROP-2 with high efficacy and low
toxicity after the progress of first-line treatment. The autophagy agents
hydroxychloroquine or chloroquine has become the only FDA (Food and Drug Administration)
approved autophagy inhibitor, and hydroxychloroquine and antibody-drug conjugate(ADC) may
have synergistic effects based on the previous work results of our research group.
Therefore,we envisage that Trastuzumab Deruxtecan(T-DXd) or Sacituzumab Govitecan (SG)
combined with hydroxychloroquine(HCQ) in the treatment of advanced breast cancer in
clinical practice has the advantages of improving efficacy and survival.
To this end, we intend to conduct a prospective,multi-center, phase I/II clinical trial
to evaluate the efficacy and safety of T-DXd or SG in combination with HCQ in patients
with advacned breast cancer.
Detailed description:
Breast cancer is the most prevalent malignant tumor in the world, and 30% of breast
cancer patients will enter the advanced stage due to treatment failure. Most patients
with advanced breast cancer have had distant organ metastasis, and the median progression
free survival period is only 1-2 years.
In the past, advanced breast cancer patients faced the dilemma of poor survival due to
the lack of precise targeted therapy. However, through a series of clinical studies,
experts in the field of advanced breast cancer have successfully expanded the indications
of ADC-based combination targeted therapy from the emergence of first generation ADC to
the third generation ADC with "bystander effect", which has significantly prolonged the
survival time of patients. Trastuzumab Deruxtecan (T-DXd) and Sacituzumab Govitecan (SG)
are new ADC drugs targeting HER2 or TROP-2 with high efficacy and low toxicity after the
progress of first-line treatment.
Because both ADC and autophagy involve lysosomes, and the relationship between ADC and
autophagy microenvironment has not been elucidated, the combination of autophagy
regulators and ADC may be a treatment option that can benefit some patients more.The
autophagy agents hydroxychloroquine or chloroquine has become the only FDA (Food and Drug
Administration) approved autophagy inhibitor. And the synergistic effect of
hydroxychloroquine and antibody-drug conjugate (ADC) has already been confirmed based on
preliminary experiments of our research group. We envisage that Trastuzumab Deruxtecan
(T-DXd) or Sacituzumab Govitecan (SG) combined with hydroxychloroquine(HCQ) in the
treatment of advanced breast cancer in clinical practice has the advantages of improving
efficacy and survival.
Therefore, we intend to further validate the efficacy and safety of the Autophagy
inhibitor hydroxychloroquine(HCQ) in combination with the latest ADC drugs (T-DXd or SG)
in a Phase I/II, randomized, controlled clinical study, in order to provide advanced
breast cancer patients with a better choice of precision targeted therapy.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Diagnosis of advanced breast cancer (female, 18 to 70 years old).
2. Pathological confirmed advanced breast cancer.
3. The patient is willing to receive SG or T-DXd treatment.
4. Failure of first-line treatment.
5. Have received no more than 3 chemotherapy schemes for metastatic breast cancer in
the past.
6. ECOG physical condition score ≤ 2 points, estimated survival time of no less than 3
months.
7. At least one measurable lesion should be present in the imaging examination within 2
weeks prior to enrollment; Or simple bone metastasis lesions.
8. LVEF≥50%.
9. Previous treatment related toxicity must be relieved to NCI CTCAE (version 5.0) ≤ 1
degree, AST and ALT ≤ 2.5 times the upper limit of normal value, and total bilirubin
≤ 1.5 times the upper limit of normal value.
10. Adequate reserve of bone marrow function: white blood cell count ≥ 3.0 × 10^9/L,
neutrophil count ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; Hemoglobin ≥ 90g/L;
Serum creatinine ≤ 1.5 times the upper limit of normal value.
Exclusion Criteria:
1. Patients suffer from various factors such as difficulty swallowing and chronic
diarrhea, which affect medication intake and absorption.
2. Individuals with severe heart disease or discomfort, expected inability to tolerate
chemotherapy, including but not limited to: fatal arrhythmias or higher-level
atrioventricular block, unstable angina, clinically significant valvular heart
disease, electrocardiogram showing transmural myocardial infarction, and
uncontrolled hypertension.
3. Patients who are known to be allergic to the active ingredients or other components
of the investigational drug.
4. Received radiotherapy, chemotherapy, endocrine therapy within 4 weeks prior to
enrollment, or is currently participating in any intervention drug clinical trials.
5. Pregnant or lactating women, women of childbearing age who refuse to take effective
contraceptive measures during the study period.
6. The researchers believe that patients are not suitable to participate in any other
circumstances of this study, which may interfere with the accompanying diseases or
conditions of the study, or have any serious medical obstacles that may affect the
safety of the subjects.
Gender:
Female
Minimum age:
18 Years
Maximum age:
70 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Address:
City:
Guangzhou
Zip:
510120
Country:
China
Status:
Recruiting
Contact:
Last name:
Jianli J Zhao, doctorate
Phone:
15920589334
Email:
zhaojli5@mail.sysu.edu.cn
Start date:
January 29, 2024
Completion date:
March 1, 2026
Lead sponsor:
Agency:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Agency class:
Other
Source:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06328387